Excess production of the pro-inflammatory interleukin IL-6 has both local and systemic tumor-promoting activity in many cancers, including ovarian cancer.
Introduction
Abnormal regulation of interleukin-6 (IL-6) and its major downstream transcription factor STAT3 is a feature of many human cancers (1) . Constitutive production of IL-6 and STAT3 occurs downstream of some oncogenic mutations in malignant cells and there is strong evidence that IL-6 is tumor-promoting in many different experimental cancer models (2) .
IL-6 is implicated in the pathophysiology of high-grade serous ovarian cancer, HGSC and clear cell ovarian cancer, CCC (3) (4) (5) . We previously demonstrated that constitutive IL-6 production by malignant cells is a major regulator of cancer-related inflammation and cytokine networks in HGSC, having important local and systemic tumor-promoting actions (3, 4, 6) .
In mouse models, anti-IL-6 antibodies have anti-tumor activity, inhibiting communication between malignant cells and stroma, reducing the leukocyte infiltrate and angiogenesis, with evidence of vessel normalization (3) . We reported some activity in a Phase II clinical trial of an anti-IL-6 antibody in patients with advanced HGSC, but sustained responses were not achieved (3) .
One of the seventeen HGSC patients treated had a partial response to anti-IL-6 therapy, seven others had periods of disease stabilization, and systemic levels of some cytokines, inflammatory and tumor biomarkers were reduced during the therapy but rose as the patients regressed.
There could be many reasons for the low efficacy of IL-6 blockade in patients with HGSC. Our previous research would suggest that a major factor might be the complexity of malignant cell cytokine production. As we have shown that inflammatory cytokines such as IL-6 interact in networks with other inflammatory mediators and growth factors in ovarian cancer cells (4, 7, 8) , we hypothesized that inhibiting constitutive IL-6 production by malignant cells may induce reciprocal feedback regulation in other signaling pathways that compensates for their action and reduces efficacy of neutralizing anti-IL-6 antibodies.
To investigate this hypothesis, we treated ovarian cancer cells with neutralizing anti-IL-6 antibodies and studied changes in intracellular signaling pathways. We found that inhibiting IL-6 signaling in these cells and ovarian cancer xenografts 
Materials and Methods

Ovarian cancer cell lines
The IGROV-1 line was recently characterized as a hypermutated line but does have TP53 and BRCA2 mutations typical of HGSC (9) . The AOCS1 cell line was established from a patient diagnosed with HGSC, Silverberg grade 3, with <1cm residual disease after primary surgery. The patient had 18 months progressionfree survival after 6 cycles carboplatin & paclitaxel adjuvant chemotherapy but showed no response to Line 2 liposomal doxorubicin. The cell line AOCS1 was established from material taken at second relapse. AOCS1 stains with antibodies to EPCAM and Pax8. The G33 cell line was established in our laboratory from omental metastases of a patient with HGSC after chemotherapy.
It has a p53 mutation W146* and is positive for EPCAM and Pax8. Quality control of all cell lines was carried out by frequent STR analysis (Eurofins MWG, Ebersberg), mycoplasma testing (InvivoGen, USA) and cell lines were used for 4-5 passages before new cells were recovered from frozen master stocks. Cells were cultured RPMI 1640 supplemented with 10% FCS and 1% pen-strep. Cells were counted using a Vi-cell cell counter (Beckman Coulter) on days 3 and 7. All technical and experimental replicates were repeated in triplicate. 
Primary cancer cells
Treatments
Cells were treated with 10Pg/ml anti-IL-6 antibody (MEDI5117) (Medimmune, Gaithersburg, MD), and 1PM Gefitinib (AstraZeneca AZD1839). MEDI5117 is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that binds to IL-6 with sub-pM affinity and neutralizes it by preventing the binding to interleukin 6 receptor (IL-6R). MEDI5117 was generated using phage display technology. It bears a triple mutation (referred to as YTE) in the Fc domain of the heavy chain that extends its stability in circulation. MEDI5117 is active in several preclinical cancer models, including NSCLC, prostate cancer, breast cancer, and ovarian cancer xenografts in mice (Manuscript in preparation, Medimmune). An IgG1 isotype control antibody was generated by MedImmune and was used at the same concentration as anti-IL-6 antibody (10Pg/ml).
Protein extraction from mouse tumors
75mg of tumor tissue was lysed with 1ml of ice-cold lysis buffer (150mM NaCl 20mM Tris, pH 7.5 1mM EDTA 1mM EGTA 1% Triton X-100) with protease and Phosphatase Inhibitors. Samples were then dissociated using gentleMACS Dissociator. After dissociation, samples were centrifuged at 1500 rpm for 2 minutes. Samples are always kept on ice between procedures. Next, using a probe sonicator set at 40% amplitude, tissues were sonicated for 5-15 seconds bursts. Sonicated samples were then rotated for 30 minutes at 4°C followed by a centrifugation for 15 minutes at 13,200 rpm at 4C. The pellet was discarded and protein concentration measured. Lysates were frozen at -80°C until loaded on gels.
Western Blotting
Cells were washed with PBS and harvested using RIPA Buffer (R0278, Sigma UK) with 1x proteinase inhibitors. Protein quantification was performed using the Bradford reagent (Sigma-Aldrich), according to the manufacturer's instructions. 
Quantifying western blots
Western blots were quantified using ImageJ analysis. The images were set to grayscale 8-type bit and a rectangular box was drawn to enclose a single lane.
The box was then selected as the first lane and the same process was repeated for the remaining of the lanes. The relative density of the contents of each lane was then plotted as histograms and a straight line was drawn underneath where the peak ends to subtract any background. The wand tool was then used to get the measurements of each profile. The ratios were obtained by normalizing the density of each band to its total protein or loading control (10) .
Immunoprecipitation
2x10
7 cells were homogenized in 1 ml of RIPA buffer (R0278, Sigma) containing phosphate inhibitor cocktail (P-5726, Sigma) and incubated on ice for 10minutes.
Samples were centrifuged at 10,000 g for 10 min at 4qC, and supernatant was recommendations.
Growth of tumors in mice and bioluminescence imaging
A total of 10x10 6 luciferase-expressing IGROV-1 cells (IGROV-1luc) were injected intraperitoneally (i.p.) into 20g 6 to 8 week-old female BALB/c nu/nu mice (purchased from Charles River, UK Ltd). These cell lines were generated as previously published (11) . Mice were observed daily for tumor growth and killed once they reached end points as defined in our Home Office Project
Licence PPL 70/7411 (20% increase in abdominal distension). All observable peritoneal tumors were dissected and weighed at the end of the experiment.
There were 8 mice in each group and two separate experiments were conducted. Statistical analyses were carried out using Prism Graph Pad software. Statistical significance was calculated using ANOVA and Student's t test. Findings are presented as standard error of the mean (SEM).
Statistical analysis
Results
IL-6 inhibition activates EGFR signaling in ovarian cancer cells
We initially tested the effect of neutralizing antibodies to IL-6 on newly established high grade serous ovarian cancer cell lines (AOCS1, G33), on freshly isolated cells from HGSC ascites and on IGROV-1, a previously characterized IL-6 producing ovarian cancer line of uncertain histotype but with TP53 and BRCA2 mutations (9) . We first asked if treating cells with a neutralizing antibody to IL-6 had an impact on other intracellular signaling pathways that were likely to be active in these cells, with a focus on ErbB Figure 1B) , as previously described (16) . In AOCS1, a combination of gefitinib and the anti-IL-6 antibody also decreased ErbB-1 phosphorylation and pERK levels, but in this instance pSTAT3 activation decreased as well ( Figure 1B 
Combined therapy that targets IL-6 and EGFR pathways reduces proliferation in 2D and 3D cultures
To investigate the biological relevance of these observations we studied growth of the cell lines in the presence of anti-IL-6 and gefitinib. AOCS1 and IGROV-1 cells were treated with the anti-IL-6 antibody, gefitinib or their combination. In 2D culture (Figure 2A, B) , IL-6 inhibition had no effect on cell proliferation as we have previously reported (3) . Gefitinib significantly reduced cell counts and this growth inhibition was greater in the combination treatment group (Figure 2A,B) .
We next used a 3D cell culture system adapted from (17) that mimics the microenvironment of the human omentum, a major site of peritoneal cancer metastasis. The model consisted of fibroblasts embedded in a collagen matrix covered by a layer of primary human mesothelial cells. AOCS1 cells were grown for two weeks in this system and then the area of malignant cell growth was measured using ImageJ ( Figure 2C,D) . Both anti-IL-6 and gefitinib reduced malignant cell growth in the organotypic cultures and the greatest inhibition was seen in the combination treatment group ( Figure 2D ).
ErbB-1 has a nuclear localization in ovarian cancer cells and this is altered by IL-6 inhibition.
We also investigated the effects of anti-IL-6 on EGFR in the cells using immunofluorescence and confocal microscopy. Confocal images and z-stack analysis of the images revealed that ErbB-1 was primarily located in the nucleus cell surface expression of ErbB1. ErbB-1 remained at the plasma membrane whether or not the cells were treated with anti-IL-6 ( Figure 3D ). In a control for the specificity of antibody staining, IGROV-1 cells were treated with siRNA to ErbB-1 or a scramble control, resulting in an almost complete removed staining in both nucleus and cytoplasm ( Figure 3E,F) . We then carried out nuclear and cytoplasmic fractionation of cells treated either with IgG control antibody or the anti-IL-6 antibody. Anti-IL-6 treatment resulted in a reduction of ErbB-1 in the nuclear fraction of IGROV-1 cells at 24 hours and three days treatment with anti-IL-6 (Fig 3G,H, Supplementary Figure 4B) . Similar results were obtained with AOCS1 (Supplementary Figure 5A) . Tubulin and nuclear lamin antibodies were used to test separation of cytoplasmic and nuclear fraction respectively, confirming the purity of the fractions ( Figure 3G ,H and Supplementary Figure   5A ).
Anti-IL-6 antibodies and E E-importin silencing both disrupt ErbB-1 nuclear localization
Next, we tested the effects of gefitinib plus/minus anti-IL-6 on nErbB-1 ( Figure   4A ). Gefitinib, anti-IL-6 treatment and their combination relocalized ERB-1 expression to the membrane.
The presence of growth factor receptors in the nucleus is well documented in several human cancers and nuclear translocation of EGFR family members has been extensively described (19) (20) (21) , but the mechanism of translocation and the role of EGF receptor family members in the nucleus of malignant cells is still unclear (22) (23) (24) . Others have reported that ErbB-1 co-localizes and interacts with E-importin in thyroid cells in order to be translocated into the nucleus (19, 22, 24) . We therefore treated AOCS1 cells with E-importin siRNA. Knock down of E-importin reduced nErbB-1; this was not observed when AOCS1 cells were treated with 'scrambled' control siRNA ( Figure 4A ).
Data from the above experiments were quantified using metamorph analysis software and correspond to an average of five microscope fields per condition ( Figure 4B ). The intensity of nErbB-1 was reduced after treating the cells with either anti-IL-6 antibody, gefitinib or the combination of both agents ( Figure 4B ).
Studies have suggested that ErbB-1 interacts with other transcription factors, such as STAT3, in the nucleus (25) . Thus, we next performed co- immunoprecipitation to see if ErbB1 co-localized with STAT3. Figure 4C shows that immunoprecipitation of ErbB-1 pulls down STAT3 in AOCS1 cells, thus suggesting that IL-6 inhibition and consequent STAT3 reduction in the nucleus might offer a possible explanation for the reduction of ErbB-1 in the nucleus.
Our work so far has shown that ovarian cancer cells are able to compensate for reduced autocrine IL-6 signaling by up regulating the EGFR signaling pathway.
In addition, it appears that in HGSC cell lines, ErbB1 is located to the nucleus and that treatment with either anti-IL-6 antibody or gefitinib, or their combination, lead to reinstatement of ErbB1 on the plasma membrane of AOCS1, G33 and IGROV-1 cells.
To test if treatment of ovarian cancer cells with both gefitinib and anti-IL-6
antibodies was able to enhance anti-tumor activity, we conducted experiments in peritoneal xenografts.
Gefitinib in combination with anti-IL-6 reduces tumor weight in mouse xenografts
We grew IGROV-1 cells as intraperitoneal xenografts in nude mice and treated the mice with the anti-human IL-6 antibody, gefitinib or both in combination.
Results of two independent experiments were combined and data are shown in CAN-14-1801 addition, we used these lysates to demonstrate that in vivo, IL-6 inhibition reduces TNFD and Jagged1 levels ( Figure 5E ), two components of the IL-6 tumor cytokine network that we previously described (3).
A summary diagram of our results is shown in Figure 6 .
Discussion
While many pre-clinical studies and clinical observations suggest that IL-6 inhibitors would be of therapeutic benefit in patients with advanced cancers (1, 3, 6, 8) , clinical trials have not shown conclusive evidence of activity, apart from in patients with Castleman's disease which is primarily driven by IL-6. In our clinical trial of a therapeutic anti-IL-6 antibody in patients with high-grade serous ovarian cancer, we found some evidence of disease stabilization but this was not sustained (3). All our evidence to date would suggest that the effects of IL-6 in this disease are driven by constitutive malignant cell production of IL-6 (3, 6-8). Thus we investigated the possibility that IL-6 inhibition might induce some reciprocal feedback regulation of other pathways.
In our study, treatment with the anti-IL-6 antibody did not completely abrogate STAT3 phosphorylation. IL-6 is not the only cytokine/growth factor that activates STAT3 hence neutralizing IL-6 would not always be expected to completely abrogate STAT3 phosphorylation. However, experimental data in the literature would suggest that partial STAT3 abrogation is therapeutically significant. For example, tumor cells that become dependent on persistent STAT3 signaling are more sensitive to STAT3 inhibition than normal cells (26) . In experiments with a lymphoma model, partial downregulation of STAT3 (40%) was responsible for strong antitumor effects in vivo (27) and in colon cancer xenografts partial inhibition of JAK/STAT3 signalling pathway is enough to suppress the growth of colon cancer xenografts (28) .
In addition, our previous research on cytokine networks in malignant cells (7) would suggest that rational combination of therapies targeting the malignant cells and their interaction with the microenvironment are worthy of investigation.
Links between the IL-6 and EGFR pathway have already been reported (29) (30) (31) (32) . thought to be of HGSC origin (9) . In addition, in human lung adenocarcinomas, mutations in the EGFR kinase domain stimulated STAT3 activation via IL-6 production (30).
Hence we decided to study the influence of IL-6 inhibition on EGFR signaling.
The cell lines that we used in our experiments did not have EGFR mutations (data not shown). In this paper we have used cell lines and primary tumor cells from peritoneal cancers that are collectively termed 'ovarian' cancers. As recently been published (37) and in the next few years as this, or transplantable cell lines derived from such mice, become more widely used, we should have more appropriate models of HGSC for preclinical experiments. IL-6 produced by malignant cells has paracrine actions not only on angiogenesis but also on the extent and phenotype of the leukocyte infiltrate (3, 7) . Hence a combination of IL-6 and EGFR inhibition may be more powerful in a syngeneic model or in patients with HGSC compared to the results described here using immunocompromised mouse xenograft models.
Nuclear EGFR signaling is thought to confer resistance to various anti-cancer therapies (23) and may explain the poor response of ovarian cancer patients to gefitinib (38) . All the cells used in this paper were resistant to the anti-EGFR antibody cetuximab (data not shown) and there was no interaction between cetuximab and anti-IL-6. The nuclear expression of ErbB-1 may explain this finding (20) . The partial restoration of membrane-localized ErbB-1 by anti-IL-6 antibody treatment may not be sufficient to permit inhibition by cetuximab. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
As both gefitinib and therapeutic anti-IL-6 antibodies have been given safely to patients with ovarian cancer, and both targets are implicated in this disease, specifically HGSC, we suggest that our data provide a rationale for testing their combination. Western blot analysis and quantification of pSTAT3, pErbB-1 and pERK in protein extracts from mouse xenografts treated with an anti-IL-6 antibody. E.
Western blot analysis and quantification of TNFD and Jagged1 in protein extracts from mouse xenografts treated with an anti-IL-6 antibody. Quantification was done using ImageJ software and is always relative to the total protein.
Results represented on graphs correspond to fold increase. 
